Cohen Yuval

USNatural personDirector

Insider

Cohen Yuval

USNatural personDirector

Transactions

Issuers

Buys / Sells

26/12

Last tx

13 Feb 2026

Behaviour

1 purchase reported after at least 12 months of silence — most recent on 09 Mar 2022.

Current positions

Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.

Issuer	Shares	Source	Last tx	Detail
Corbus Pharmaceuticals Holdings, Inc.	174,316	reported	13 Feb 2026	tx 79+8,925,571−242,987

Recent transactions

Date	Type	Issuer	Qty	Price	Signals
13 Feb 2026	SALE	Corbus Pharmaceuticals Holdings, Inc.	13,871	7.78 USD
14 Jan 2026	GRANT_AWARD	Corbus Pharmaceuticals Holdings, Inc.	50,000	0.00 USD
14 Jan 2026	GRANT_AWARD	Corbus Pharmaceuticals Holdings, Inc.	150,000	0.00 USD	deriv
24 Oct 2025	SALE	Corbus Pharmaceuticals Holdings, Inc.	18,660	17.01 USD
27 Oct 2025

InsiderLens aggregates public information issued by financial regulators (SEC, AMF, FCA, BaFin, AFM, FI, HKEX, ASX). The service constitutes neither investment advice nor a recommendation to buy or sell. Past performance is no guarantee of future results. Investing in financial instruments carries the risk of capital loss.

Current positions

Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.

Issuer	Shares	Source	Last tx	Detail
Corbus Pharmaceuticals Holdings, Inc.	174,316	reported	13 Feb 2026	tx 79+8,925,571−242,987

Recent transactions

Date	Type	Issuer	Qty	Price	Signals
13 Feb 2026	SALE	Corbus Pharmaceuticals Holdings, Inc.	13,871	7.78 USD
14 Jan 2026	GRANT_AWARD	Corbus Pharmaceuticals Holdings, Inc.	50,000	0.00 USD
14 Jan 2026	GRANT_AWARD	Corbus Pharmaceuticals Holdings, Inc.	150,000	0.00 USD	deriv
24 Oct 2025	SALE	Corbus Pharmaceuticals Holdings, Inc.	18,660	17.01 USD
27 Oct 2025